Impact of Antimicrobial Resistance in Diabetic Foot Infections

Main Article Content

Tarun Singh et al.


A terrible micro-vascular consequence called diabetic foot ulcers (DFUs) is to blame for a significant rise in morbidity and mortality. DFU is a complex complication of infection, neuropathy, and peripheral artery disorders. Microbial flora causes conditions ranging from superficial cellulitis to chronic osteomyelitis and lower limb amputations due to gangrenous extremities. Antibiotic treatment is not mandatory without soft tissue or bone infection evidences. Bacteria (particularly gram positive coccii) must be treated empirically for infections ranging from mild to moderate, while obligatory anaerobes and aggressive gram-negative aerobes must be targeted by wide spectrum antibiotics for severe infections or infections brought on by drug-resistant organisms. Neuropathic ulceration commonly leads to common diabetic foot infections. Diabetic foot infections can cause osteomyelitis, especially when they are linked to serious and foot ulcers which are chronic in nature. In this study we assessed various published trailsbased on clinical setting for diabetic foot ulcer, infections and drug resistance cumulatively. It is observed diabetes foot infections should receive individualized antimicrobial treatment based on the severity of the condition, the microbial pathogen, and the host for minimizing antimicrobial resistance.

Article Details

How to Cite
Tarun Singh et al. (2023). Impact of Antimicrobial Resistance in Diabetic Foot Infections. Journal of Coastal Life Medicine, 11(1), 487–502. Retrieved from
Author Biography

Tarun Singh et al.

Tarun Singh1, Manish Kumar Maity2, Rabinoor Singh3, Navpreet Singh Babbar4, Ayush Kumar5, Prashant Das6, Anuj Malik7*, Mayank Jain8, Divya Tandon9, Bimal K Agrawal10


1-9Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana - 133207, Ambala, India

10MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana - 133207, Ambala, India


. Roglic G. WHO Global report on diabetes: a summary. Int J Noncommun Dis 2016; 1(1):3.

. Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006; 29(6):1288–93.

. Hobizal KB, Wukich DK. Diabetic foot infections: current concept review. Diabet Foot Ankle 2012; 3:1–8.

. Wukich DK, Raspovic KM, Suder NC. Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot Ankle Spec 2018; 11(1):17–21.

. Fincke BG, Miller DR, Turpin R. A classification of diabetic foot infections using ICD-9-CM codes: application to a large computerized medical database. BMC Health Serv Res 2010; 10(1):192.

. Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007; 4(4):286–7.

. Robbins JM, Strauss G, Aron D, et al. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc 2008; 98(6):489–93.

. Saltoglu N, Ergonul O, Tulek N, et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. Int J Infect Dis 2018; 70:10–4.

. Malone M, Johani K, Jensen SO, et al. Next generation DNA sequencing of tissues from infected diabetic foot ulcers. EBioMedicine2017; 21:142–9.

. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053):1545–602.

. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376(24):2367–75.

. Lazzarini PA, Pacella RE, Armstrong DG, et al. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. Diabet Med 2018; 35(9):1297–9.

. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50(1):18–25.

. Lipsky BA, Berendt AR, Deery HG, et al, Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections.Clin Infect Dis 2004; 885–910.

. Reiber GE, Vileikyte L, Boyko EJ, et al. Chastain et al Causal pathways for incident lowerextremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22(1):157–62.

. Noor S, Khan RU, Ahmad J. Understanding diabetic foot infection and its management. Diabetes MetabSyndr 2017; 11(2):149–56.

. Walsh JW, Hoffstad OJ, Sullivan MO, et al. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med 2016; 33(11):1493–8.

. Nikoloudi M, Eleftheriadou I, Tentolouris A, et al. Diabetic foot infections: update on management. Curr Infect Dis Rep 2018; 20(10):40.

. Lipsky BA, Berendt AR, Deery HG, et al, Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections.PlastReconstrSurg 2006; 117(7 Suppl):212S–38S.

. Frykberg RG, Cook JJ, Simonson DC. Epidemiology and health care cost of diabetic foot problems. In: Veves A, Giurini JM, Guzman RJ, editors. The Diabetic Foot. Cham (Switzerland): Humana Press; 2018. P - 3–17.

. Ulbrecht JS, Cavanagh PR, Caputo GM. Foot problems in diabetes: an overview. Clin Infect Dis 2004; 39(Supplement_2):S73–82.

. Joshi N, Caputo GM, Weitekamp MR, et al. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341(25):1906–12.

. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26(3–4):259–65.

. Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci 2016; 351(2):201–11.

. Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14(1):29–34.

. Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007; 40(8): 1037–44.

. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med 2005; 33(7):1624–33.

. Dejani NN, Brandt SL, Pin˜eros A, et al. Topical prostaglandin E analog restores defective dendritic cell-mediated Th17 host defense against methicillinresistant Staphylococcus aureus in the skin of diabetic mice. Diabetes 2016; 65(12):3718–29.

. Domingueti CP, Dusse LM, Carvalho MD, et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications 2016; 30(4):738–45.

. Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol 2016; 12(1):13–26.

. Lipsky BA. Diabetic foot infections: current treatment and delaying the ‘post-antibiotic era’. Diabetes Metab Res Rev 2016; 32:246–53.

. Goff DA, Kullar R, Goldstein EJC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis 2017; 17(2):e56–63.

. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. London (United Kingdom): Review on Antimicrobial Resistance; 2017.

. U, kay I, Gariani K, Dubois-Ferrie`re V, et al. Diabetic foot infections: recent literature and cornerstones of management. CurrOpin Infect Dis 2016; 29(2):145–52.

. Lipsky BA, Itani KM, Weigelt JA, et al. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis 2011; 15(2):e140–6.

. Zenelaj B, Bouvet C, Lipsky BA, et al. Do diabetic foot infections with methicillinresistant Staphylococcus aureus differ from those with other pathogens? Int J Low Extrem Wounds 2014; 13(4):263–72.

. LaSalvia MT, Karchmer AW. Microbiology and treatment of diabetic foot infection. In: Veves A, Giurini JM, Guzman RJ, editors. The Diabetic Foot. Cham (Switzerland): Humana Press; 2018. p. 267–79.

. Xie X, Bao Y, Ni L, et al. Bacterial profile and antibiotic resistance in patients with diabetic foot ulcer in Guangzhou, Southern China: focus on the differences among different Wagner’s Grades, IDSA/IWGDF Grades, and ulcer types. Int J Endocrinol 2017; 2017:8694903.

. Sekhar SM, Vyas N, Unnikrishnan M, et al. Antimicrobial susceptibility pattern in diabetic foot ulcer: a pilot study. Ann Med Health Sci Res 2014; 4(5):742–5.

. Vatan A, Saltoglu N, Yemisen M, et al. Association between biofilm and multi/ extensive drug resistance in diabetic foot infection. Int J ClinPract 2018; 72(3): e13060.

. Mottola C, Matias CS, Mendes JJ, et al. Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections. BMC Microbiol 2016; 16(1):119.

. Lipsky BA, Arago´n-Sa´nchez J, Diggle M, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev 2016; 32(Suppl 1):45–74.

. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54(12):e132–73.

. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8):801–10.

. Game F. Classification of diabetic foot ulcers. Diabetes Metab Res Rev 2016; 32(Suppl 1):186–94.

. Giurato L, Meloni M, Izzo V, et al. Osteomyelitis in diabetic foot: a comprehensive overview. World J Diabetes 2017; 8(4):135–42.

. van Asten SA, Jupiter DC, Mithani M, et al. Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int Wound J 2017; 14(1):142–8.

. Victoria van Asten SA, Geradus Peters EJ, Xi Y, et al. The role of biomarkers to diagnose diabetic foot osteomyelitis.A meta-analysis.Curr Diabetes Rev 2016; 12(4):396–402.

. Peterson N, Widnall J, Evans P, et al. Diagnostic imaging of diabetic foot disorders. Foot Ankle Int 2017; 38(1):86–95.

. Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. Diabetes Care 2017; 40(8):1111–20.

. Rogers LC, Frykberg RG. The diabetic charcot foot. In: Veves A, Giurini JM, Guzman RJ, editors. The Diabetic Foot. Cham (Switzerland): Humana Press; 2018. p. 391–413.

. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 2008; 31(4): 637–42.

. Senneville E, Robineau O. Treatment options for diabetic foot osteomyelitis. Expert OpinPharmacother 2017; 18(8):759–65.392 Chastain et al

. Vris A, Massa E, Ahluwalia R, et al. Primary results of bone biopsies in outpatients with neuropathic ulcers: comparison with wound swabs and superficial tissue samples. Foot & Ankle Orthopaedics 2017; 2(3). 2473011417S000078.

. Nelson A, Wright-Hughes A, Backhouse MR, et al. CODIFI (Concordance in Diabetic Foot Ulcer Infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ Open 2018;8(1): e019437.

. SelvaOlid A, Sola I, Barajas-Nava LA, et al. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev 2015 ;( 9):CD009061.

. Tchero H, Kangambega P, Noubou L, et al. Antibiotic therapy of diabetic foot infections: a systematic review of randomized controlled trials. Wound Repair Regen 2018; 26(5):381–91.

. Dumville JC, Lipsky BA, Hoey C, et al. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 2017; 6: CD011038.

. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults.Clin Infect Dis 2012; 54(3):393–407.

. Li HK, Scarborough M, Zambellas R, et al. Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomized controlled trial. Trials 2015; 16:583.

. Scarborough M, Li HK, Rombach I, et al. Oral versus intravenous antibiotics for the treatment of bone and joint infection (OVIVA): a multicentre randomized controlled trial in Orthopaedic Proceedings. 2017: The British Editorial Society of Bone & Joint Surgery.

. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection 2013; 41(1):175–86.

. Johani K, Fritz BG, Bjarnsholt T, et al. Understanding the microbiome of diabetic foot osteomyelitis: insights from molecular and microscopic approaches. ClinMicrobiol Infect 2019; 25(3):332–9.

. van Asten SA, La Fontaine J, Peters EJ, et al. The microbiome of diabetic foot osteomyelitis.Eur J ClinMicrobiol Infect Dis 2016; 35(2):293–8.

. Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015; 38(2):302–7.

. Chu Y, Wang C, Zhang J, et al. Can we stop antibiotic therapy when signs and symptoms have resolved in diabetic foot infection patients? Int J Low Extrem Wounds 2015; 14(3):277–83.

. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014 ;(2):CD009122.

. Paneni F, Luscher TF. Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Med 2017; 130(6S):S18–29.

. Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on ardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(12): 951–64.

. Hinchliffe RJ, Brownrigg JR, Andros G, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev 016; 32(Suppl 1):136–44.

. Fife CE, Carter MJ, Walker D, et al. Diabetic foot ulcer off-loading: the gap between evidence and practice. Data from the US Wound Registry.Adv Skin Wound Care 2014; 27(7):310–6.

.Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care 2014; 37(3):789–95. 73.

. Fedorko L, Bowen JM, Jones W, et al. Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: a prospective, double-blind, randomized controlled clinical trial. Diabetes Care 2016; 39(3):392–9.

. Huang ET, Mansouri J, Murad MH, et al. A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. Undersea Hyperb Med 2015; 42(3):205–47.

. Liu Z, Dumville JC, Hinchliffe RJ, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev 2018 ;(10):CD010318.

. Cruciani M, Lipsky BA, Mengoli C, et al. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev 2013 ;(8):CD006810.

. Edmonds M, La´zaro-Martı´nez JL, Alfayate-Garcı´a JM, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol 2018; 6(3):186–96.

. Callahan D, Keeley J, Alipour H, et al. Predictors of severity in diabetic foot infections. Ann VascSurg 2016; 33:103–8.

.Uysal S, Arda B, Tas‚bakan MI, et al. Risk factors for amputation in patients with diabetic foot infection: a prospective study. Int Wound J 2017; 14(6):1219–24.

. Zhan LX, Branco BC, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing. J VascSurg 2015; 61(4):939–44.

. Dubsky´ M, Jirkovska´ A, Bem R, et al. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. Int Wound J 2013; 10(5):555–61.

. O rneholm H, Apelqvist J, Larsson J, et al. Recurrent and other new foot ulcers after healed plantar forefoot diabetic ulcer. Wound Repair Regen 2017; 25(2): 309–15.

. Keller SC, Dzintars K, Gorski LA, et al. Antimicrobial agents and catheter complications in outpatient parenteral antimicrobial therapy. Pharmacotherapy 2018; 38(4):476–81.

. Keller SC, Williams D, Gavgani M, et al. Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy. Clin Infect Dis 2018; 66(1): 11–9.

. Schrank GM, Wright SB, Branch-Elliman W, et al. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy. Infect Control HospEpidemiol 2018; 39(8):947–54.

Chastain et al

. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42(12):e108–10.

. Wigen CL, Goetz MB. Serotonin syndrome and linezolid.Clin Infect Dis 2002; 34(12):1651–2.

. Chatterjee A, Modarai M, Naylor NR, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis 2018; 18(12):e368–78.

. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases Society of America (IDSA) and Society for health care epidemiology of America (SHEA). Clin Infect Dis 2018; 66(7):e1–48.